Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells

BACKGROUND: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene expression in CD8 + T cells and demonstrated that GSK-3 inhibition is as effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Gary, Cavalcante, Ludimila, Giles, Francis J., Taylor, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472445/
https://www.ncbi.nlm.nih.gov/pubmed/36104795
http://dx.doi.org/10.1186/s13045-022-01352-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472445/
https://www.ncbi.nlm.nih.gov/pubmed/36104795
http://dx.doi.org/10.1186/s13045-022-01352-x

Ejemplares similares